Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: alum adjuvant Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
5
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine

NCT05065983
View directory record Official record
Conditions
Chikungunya Virus
Interventions
CHIKV VLP, adjuvanted
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 29, 2026, 4:57 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine

NCT03776994
View directory record Official record
Conditions
Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases, Encephalomyelitis, Venezuelan Equine, Brain Diseases, Central Nervous System Diseases, Central Nervous System Viral Diseases, Alphavirus Infections, Togaviridae Infections, RNA Virus Infections, Central Nervous System Infections, Encephalomyelitis, Physiological Effects of Drugs, Vaccines, Encephalomyelitis, Equine, Nervous System Diseases
Interventions
Vaccinations on Day 0, Day 28, and Day 140
Biological
Lead sponsor
SRI International
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plymouth, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)

NCT03992872
View directory record Official record
Conditions
Chikungunya
Interventions
Chikungunya
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Fort Deterick, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

NCT00529399
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
GAD-Alum, GAD-Alum and Aluminum hydroxide, Aluminum hydroxide
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

NCT03010228
View directory record Official record
Conditions
Lyme Borreliosis, Nervous System
Interventions
VLA15 with Alum, VLA15 without Alum
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 39 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
4
States / cities
La Mesa, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

NCT00705835
View directory record Official record
Conditions
Prostate Cancer
Interventions
rsPSMA protein plus Alhydrogel® vaccine
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

NCT00001096
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Suspended Phase 1 Interventional

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

NCT06680479
View directory record Official record
Conditions
HIV-1
Interventions
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin

NCT00812071
View directory record Official record
Conditions
Healthy
Interventions
RiVax
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 31 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chesapeake, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

NCT00344539
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 29, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

NCT02606994
View directory record Official record
Conditions
Mucositis, Neoplasms
Interventions
Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
Drug
Lead sponsor
Oral Defense, LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers

NCT01657929
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
H5-VLP + GLA-AF, H5-VLP alone, H5-VLP + Alhydrogel(R), Licensed H5N1 vaccine
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 49 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

NCT03039790
View directory record Official record
Conditions
Healthy Volunteers, Norovirus
Interventions
NoV Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 29, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults

NCT02771730
View directory record Official record
Conditions
Healthy Volunteer, HIV Vaccine
Interventions
Ad4-mgag, Ad4-EnvC150, Placebo Comparator, AIDSVAX B/E
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

NCT02475278
View directory record Official record
Conditions
Norovirus, Healthy Participants
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Experimental Vaccine for Malaria

NCT00114010
View directory record Official record
Conditions
Malaria
Interventions
AMA1/Alhydrogel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 29, 2026, 4:57 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 29, 2026, 4:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

NCT04177355
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 29, 2026, 4:57 AM EDT